Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes.

Adolescent Adult Age Factors Aged Aged, 80 and over Collagen Type IV / analysis Cross-Sectional Studies Diabetes Mellitus, Type 2 / blood Dyslipidemias / complications Female Humans Liver Cirrhosis / diagnosis Male Middle Aged Non-alcoholic Fatty Liver Disease / blood Platelet Count ROC Curve Young Adult

Journal

Hepatology communications

ISSN: 2471-254X

Titre abrégé: Hepatol Commun

Pays: United States

ID NLM: 101695860

Informations de publication

Date de publication:
04 2021

Historique:

received: 16 07 2020

revised: 06 10 2020

accepted: 16 10 2020

entrez: 16 4 2021

pubmed: 17 4 2021

medline: 17 4 2021

Statut: epublish

Résumé

This study aimed to examine whether the diagnostic accuracy of four noninvasive tests (NITs) for detecting advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is maintained or is inferior to with or without the presence of type 2 diabetes. Overall, 874 patients with biopsy-proven NAFLD were enrolled. After propensity-score matching by age, sex, and the prevalence of dyslipidemia, 311 patients were enrolled in each group of with or without diabetes. To evaluate the effect of diabetes, we compared the diagnostic accuracy of the fibrosis-4 (FIB-4) index, the NAFLD fibrosis score (NFS), the aspartate aminotransferase to platelet ratio index (APRI), and type IV collagen 7S (COL4-7S) in patients with NAFLD with and without diabetes. The areas under the receiver operating characteristic curve (AUROC) for identifying advanced fibrosis in patients without diabetes were 0.879 for the FIB-4 index, 0.851 for the NFS, 0.862 for the APRI, and 0.883 for COL4-7S. The AUROCs in patients with diabetes were 0.790 for the FIB-4 index, 0.784 for the NFS, 0.771 for the APRI, and 0.872 for COL4-7S. The AUROC of COL4-7S was significantly larger than that of the other NITs in patients with NAFLD with diabetes than in those without diabetes. The optimal high and low cutoff points of COL4-7S were 5.9 ng/mL and 4.8 ng/mL, respectively. At the low cutoff point, the accuracy of COL4-7S was better than that of the other NITs, especially in patients with diabetes.

Identifiants

DOI: 10.1002/hep4.1637 PMID: 33860115 PMC: PMC8034577

pubmed: 33860115

doi: 10.1002/hep4.1637

pii: 02009842-202104000-00004

pmc: PMC8034577

doi:

Substances chimiques

Collagen Type IV 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

559-572

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73‐84.

Angulo P, Kleiner DE, Dam‐Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389‐397.

Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, et al. Surveillance of hepatocellular carcinoma in nonalcoholic fatty liver disease. Diagnostics 2020:10:579.

Sumida Y, Shima T, Mitsumoto Y, Katayama T, Umemura A, Yamaguchi K, et al. Epidemiology: pathogenesis, and diagnostic strategy of diabetic liver disease in Japan. Int J Mol Sci 2020;21:4337.

Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 2017;8:397‐410.

Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009;57:205‐210.

Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Non‐alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854‐858.

Leite NC, Villela‐Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011;31:700‐706.

Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol 2019;13:849‐866.

Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care 2017;40:419‐430.

American Diabetes Association . Standards of Medical Care in Diabetes—2019 abridged for primary care providers. Clin Diabetes 2019;37:11‐34.

Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do diabetologists stand? Clin Diabetes Endocrinol 2020;5:9.

Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies. Liver Int 2008;28:705‐712.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328‐357.

Williamson RM, Price JF, Hayes PC, Glancy S, Frier BM, Johnston GI, et al. Prevalence and markers of advanced liver disease in type 2 diabetes. QJM 2012;105:425‐432.

American Diabetes Association . Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183‐1197.

Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander‐Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467‐2474.

Japanese Society for the Study of Obesity . New criteria of obesity in Japanese. J Jpn Soc Study Obes 2000;6:18‐28.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313‐1321.

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317‐1325.

Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846‐854.

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518‐526.

Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104‐1112.

Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 2018;68:335‐352.

Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi‐center study. J Gastroenterol 2018;53:1216‐1224.

McPherson S, Hardy T, Dufour JF, Petta S, Romero‐Gomez M, Allison M, et al. Age as a confounding factor for the accurate non‐invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740‐751.

Leeming DJ, Nielsen MJ, Dai Y, Veidal SS, Vassiliadis E, Zhang C, et al. Enzyme‐linked immunosorbent serum assay specific for the 7S domain of collagen type IV (P4NP 7S): a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res 2012;42:482‐493.

Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005;11:255‐259.

Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011;46:257‐268.

Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, et al. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol 2007;42:375‐381.

Okanoue T, Ebise H, Kai T, Mizuno M, Shima T, Ichihara J, et al. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol 2018;53:129‐139.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) . EASL‐EASD‐EASO Clinical Practice Guidelines for the management of non‐alcoholic fatty liver disease. J Hepatol 2016;64:1388‐1402.

Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2014;49:1477‐1484.

Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132‐138.

Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, et al. Type 2 diabetes mellitus: a risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease. J Gastroenterol Hepatol 2019;34:2011‐2018.

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta‐analysis. J Hepatol 2019;71:793‐801.

Jesri A, Okonofua EC, Egan BM. Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2005;7:705‐711; quiz 712‐713.

Taniguchi A, Fukushima M, Seino Y, Sakai M, Yoshii S, Nagasaka S, et al. Platelet count is independently associated with insulin resistance in non‐obese Japanese type 2 diabetic patients. Metabolism 2003;52:1246‐1249.

Cho NH, Becker DJ, Ellis D, Kuller LH, Drash AL, Orchard TJ. Spontaneous whole blood platelet aggregation, hematological variables and complications in insulin‐dependent diabetes mellitus: the Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 1992;6:12‐18.

Brown AS, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:802‐807.

Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin‐6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784‐2789.

Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, et al. Diabetes impacts prediction of cirrhosis and prognosis by non‐invasive fibrosis models in non‐alcoholic fatty liver disease. Liver Int. 2018;38:1793‐1802.

Karsdal MA, Nielsen SH, Leeming DJ, Langholm LL, Nielsen MJ, Manon‐Jensen T, et al. The good and the bad collagens of fibrosis—their role in signaling and organ function. Adv Drug Deliv Rev 2017;1:43‐56.

Karsdal MA, Genovese F, Madsen EA, Manon‐Jensen T, Schuppan D. Collagen and tissue turnover as a function of age: implications for fibrosis. J Hepatol 2016;64:103‐109.

Fang KC, Cheng YL, Su CW, Wang YJ, Lan KH, Huo TI, et al. Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. J Chin Med Assoc 2017;80:125‐132.

Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME; NASHNET . Screening for non‐alcoholic fatty liver disease in persons with type 2 diabetes in the u.s. is cost effective: a comprehensive cost‐utility analysis. Gastroenterology 2020 Aug 5. https://doi.org/10.1053/j.gastro.2020.07.050 . [Epub ahead of print]

doi: 10.1053/j.gastro.2020.07.050

Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, et al. Computer‐assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009;49:1236‐1244.